Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22120736 | 0.80 | P2RX7 (0.34) | — | |
| SCHEMBL2260137 | 0.79 | NR1H2 (0.42) | USP30USP2SMN1; SMN2NR1H2RORC | |
| SCHEMBL24700430 | 0.79 | USP30 (0.38) | USP30AAK1BUB1USP2SMN1; SMN2 | |
| SCHEMBL24807801 | 0.77 | USP30 (0.35) | USP30AAK1BUB1 | |
| SCHEMBL23538597 | 0.77 | USP30 (0.39) | USP30USP2SMN1; SMN2NR1H2RORC | |
| SCHEMBL22120969 | 0.75 | MEN1 (0.41) | SMN1; SMN2NR1H2RORC | |
| SCHEMBL26963361 | 0.75 | USP30 (0.34) | USP30AAK1BUB1 | |
| SCHEMBL24700431 | 0.74 | USP30 (0.36) | USP30AAK1BUB1USP2SMN1; SMN2 | |
| SCHEMBL1763807 | 0.73 | USP30 (0.41) | USP30USP2SMN1; SMN2NR1H2 | |
| SCHEMBL18150772 | 0.73 | USP30 (0.37) | USP30AAK1BUB1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897630-B1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORP (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-113874015-A | Thienopyridine inhibitors of RIPK2 | 细胞基因公司 | 2021-12-31 | — | — | CN | disclosed |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | CELGENE CORPORATION (US) | 2021-11-09 | — | — | US | disclosed |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | CELGENE CORPORATION (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORPORATION | 2020-06-25 | — | — | US | disclosed |
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORPORATION | 2020-06-25 | — | — | US | disclosed |
| WO-2020132384-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORPORATION (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | USP30 2566/4885AAK1 267/4885BUB1 2048/4885 |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | RIPK2, RIPK1, RIPK4 | USP30 2566/4885AAK1 267/4885BUB1 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.